Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study
暂无分享,去创建一个
L. Wain | N. Shrine | R. Allen | M. Obeidat | Y. Bossé | I. Sayers | R. Hubbard | M. Tobin | I. Hall | I. Noth | A. Henry | D. Nickle | D. Schwartz | D. Rassl | T. Fingerlin | W. Fahy | W. Timens | T. Maher | P. Molyneaux | I. Yang | B. Guillen-Guio | C. Flores | R. Jenkins | A. Millar | R. McAnulty | V. Navaratnam | I. Hall | M. Whyte | N. Hirani | A. John | R. Marshall | J. Oldham | H. Parfrey | J. Porte | H. Booth | M. Hill | Justin M Oldham | T. Okamoto | M. Whyte | G. Saini | R. Jenkins | E. Oballa | R. Braybrooke | N. Thompson | D. A. Schwartz | Shwu-Fan Ma | P. L. Molyneaux | Carlos Flores | Joanne Porte | Tsukasa Okamoto | Alison E John | Ivana V. Yang | Richard Hubbard | Norma Thompson | Helen Booth | Simon P. Hart | Michael Hill | Nik Hirani | Ann B. Millar | Richard P. Marshall | Don D. Sin | Toby M. Maher | Richard P. Marshall | Joanne Porte | Tsukasa Okamoto | Alison E John | Ivana V. Yang | Norma Thompson | Helen Booth | A. Millar | Don D. Sin | Michael Hill | I. Sayers | P. Molyneaux | Moira K B Whyte | Richard B Hubbard
[1] D. Schwartz,et al. Pulmonary fibrosis in the era of stratified medicine , 2016, Thorax.
[2] S. Traynelis,et al. Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use. , 2016, Pharmacology & therapeutics.
[3] Brent S. Pedersen,et al. Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia , 2016, BMC Genetics.
[4] Rachel C Chambers,et al. Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF , 2016, Thorax.
[5] G. Laurent,et al. Epigenetic regulation of cyclooxygenase-2 by methylation of c8orf4 in pulmonary fibrosis , 2016, Clinical science.
[6] Biao Xu,et al. Association Between the MUC5B Promoter Polymorphism rs35705950 and Idiopathic Pulmonary Fibrosis , 2015, Medicine.
[7] L. Wain,et al. Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK Biobank , 2015, The Lancet. Respiratory medicine.
[8] Shandra L. Protzko,et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. , 2015, American journal of respiratory and critical care medicine.
[9] Mulin Jun Li,et al. Nature Genetics Advance Online Publication a N a Ly S I S the Support of Human Genetic Evidence for Approved Drug Indications , 2022 .
[10] S. Mane,et al. Exome Sequencing Links Mutations in PARN and RTEL1 with Familial Pulmonary Fibrosis and Telomere Shortening , 2015, Nature Genetics.
[11] J. Liao,et al. The Rho Kinases: Critical Mediators of Multiple Profibrotic Processes and Rational Targets for New Therapies for Pulmonary Fibrosis , 2015, Pharmacological Reviews.
[12] Zora Modrusan,et al. Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis , 2014, Thorax.
[13] Joyce S Lee,et al. Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. , 2014, The Lancet. Respiratory medicine.
[14] W. Coward,et al. A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenase-2 in idiopathic pulmonary fibrosis , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[15] J. Leader,et al. C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis. , 2014, American journal of respiratory and critical care medicine.
[16] D. Diviani,et al. A-kinase anchoring protein-Lbc promotes pro-fibrotic signaling in cardiac fibroblasts. , 2014, Biochimica et biophysica acta.
[17] L. Wain,et al. GSTCD and INTS12 Regulation and Expression in the Human Lung , 2013, PloS one.
[18] F. Sciurba,et al. Plasma B Lymphocyte Stimulator and B Cell Differentiation in Idiopathic Pulmonary Fibrosis Patients , 2013, The Journal of Immunology.
[19] Don D. Sin,et al. Refining Susceptibility Loci of Chronic Obstructive Pulmonary Disease with Lung eqtls , 2013, PloS one.
[20] Ivana V. Yang,et al. Expression of cilium-associated genes defines novel molecular subtypes of idiopathic pulmonary fibrosis , 2013, Thorax.
[21] I. Noth,et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. , 2013, JAMA.
[22] Naftali Kaminski,et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. , 2013, The Lancet. Respiratory medicine.
[23] Brent S. Pedersen,et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis , 2013, Nature Genetics.
[24] David C. Nickle,et al. Lung eQTLs to Help Reveal the Molecular Underpinnings of Asthma , 2012, PLoS genetics.
[25] D. Diviani,et al. A-Kinase-Anchoring Protein–Lbc Anchors IκB Kinase β To Support Interleukin-6-Mediated Cardiomyocyte Hypertrophy , 2012, Molecular and Cellular Biology.
[26] R. Hubbard,et al. The rising incidence of idiopathic pulmonary fibrosis in the UK , 2011, Thorax.
[27] H. Collard,et al. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. , 2011, American journal of respiratory and critical care medicine.
[28] P. D. de Jong,et al. Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a dutch cohort. , 2010, American journal of respiratory and critical care medicine.
[29] W. Coward,et al. The pathogenesis of idiopathic pulmonary fibrosis , 2010, Therapeutic advances in respiratory disease.
[30] M. Giel-Moloney,et al. The Lbc Rho Guanine Nucleotide Exchange Factor/α-Catulin Axis Functions in Serotonin-induced Vascular Smooth Muscle Cell Mitogenesis and RhoA/ROCK Activation* , 2010, The Journal of Biological Chemistry.
[31] M. Venere,et al. The Rho Guanine Nucleotide Exchange Factor AKAP13 (BRX) Is Essential for Cardiac Development in Mice* , 2010, The Journal of Biological Chemistry.
[32] P. Weinreb,et al. Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q). , 2009, The American journal of pathology.
[33] Yan A. Su,et al. Brx Mediates the Response of Lymphocytes to Osmotic Stress Through the Activation of NFAT5 , 2009, Science Signaling.
[34] S. Kudoh,et al. A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis , 2008, Journal of Medical Genetics.
[35] B. Crestani,et al. Dendritic cells accumulate in human fibrotic interstitial lung disease. , 2007, American journal of respiratory and critical care medicine.
[36] G. Abecasis,et al. Optimal designs for two‐stage genome‐wide association studies , 2007, Genetic epidemiology.
[37] P. Donnelly,et al. A new multipoint method for genome-wide association studies by imputation of genotypes , 2007, Nature Genetics.
[38] R. Chambers,et al. Ligation of protease-activated receptor 1 enhances alpha(v)beta6 integrin-dependent TGF-beta activation and promotes acute lung injury. , 2006, The Journal of clinical investigation.
[39] V. Soumelis,et al. Cutting Edge: Nonproliferating Mature Immune Cells Form a Novel Type of Organized Lymphoid Structure in Idiopathic Pulmonary Fibrosis1 , 2006, The Journal of Immunology.
[40] Tomoshige Kino,et al. Rho Family Guanine Nucleotide Exchange Factor Brx Couples Extracellular Signals to the Glucocorticoid Signaling System* , 2006, Journal of Biological Chemistry.
[41] A. Hall,et al. Activated Gαq family members induce Rho GTPase activation and Rho‐dependent actin filament assembly , 2002, FEBS letters.
[42] L. Quarles,et al. Calcium-sensing receptor activation of rho involves filamin and rho-guanine nucleotide exchange factor. , 2002, Endocrinology.
[43] Jonathan Haines,et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. , 2002, American journal of respiratory and critical care medicine.
[44] Paul J. Friedman,et al. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors , 2002, American journal of respiratory and critical care medicine.
[45] J. Scott,et al. Akap-lbc Anchors Protein Kinase a and Nucleates G␣ 12 -selective Rho-mediated Stress Fiber Formation* , 2022 .
[46] G. Laurent,et al. Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice. , 2001, The American journal of pathology.
[47] C. Buckmaster,et al. A Rho Exchange Factor Mediates Thrombin and Gα12-induced Cytoskeletal Responses* , 1999, The Journal of Biological Chemistry.
[48] D. Lamb,et al. THE IMMUNOLOGICAL ARCHITECTURE OF B‐LYMPHOCYTE AGGREGATES IN CRYPTOGENIC FIBROSING ALVEOLITIS , 1996, The Journal of pathology.
[49] M. Burdick,et al. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. , 1995, The Journal of clinical investigation.
[50] R. D. du Bois,et al. Immunohistological analysis of lung tissue from patients with cryptogenic fibrosing alveolitis suggesting local expression of immune hypersensitivity. , 1985, Thorax.
[51] A. Azuma,et al. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis , 2015 .
[52] Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. , 2015, The New England journal of medicine.
[53] M. L. R. D. Christenson,et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management , 2012 .